Amalgamated Financial’s Entrada Therapeutics TRDA Stock Holding History

Amalgamated Financial’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$13K	Buy	+1,350	New	+$14.5K	﹤0.01%	2852

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Amalgamated Financial's TRDA Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Entrada Therapeutics (TRDA) in Q1 2022: 1,350 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #2852 among its holdings.

48 funds tracked by Wall St. Rank hold TRDA as of Q1 2022.

Amalgamated Financial held 1,350 shares of Entrada Therapeutics worth $13K as of Q1 2022.
Entrada Therapeutics was a new Amalgamated Financial position in Q1 2022.
Entrada Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2852 holding.
48 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.